GSK to acquire Human Genome Sciences for USD14.25 per share in cash

GlaxoSmithKline plc and Human Genome Sciences announced that the companies have entered into a definitive agreement under which GSK will acquire HGS for USD14.25 per share in cash. The transaction values HGS at approximately USD3.6 billion on an equity basis, or approximately USD3 billion net of cash and debt, and represents a premium of 99% to the HGS closing price of USD7.17 per share on 18 April 2012, the last day of trading before HGS publicly disclosed GSK’s initial private offer.

Read full story >>

AstraZeneca reports terms of David Brennan’s retirement
AstraZeneca have reported on the remuneration arrangements relating to David Brennan’s retirement...

GlaxoSmithKline celebrates its role in supporting the biggest anti-doping operation in the history of the Olympic Games
GSK marks its role as Official Laboratory Services Provider for the London 2012 Olympic and Paralympic Games by launching its first UK advertising campaign...
 

U.S. FDA approves Gilead ’s Truvada® for reducing the risk of acquiring HIV
Gilead Sciences, Inc., has announced that the U.S. Food and Drug Administration has approved once-daily oral Truvada®...

Ilka Diester wins Boehringer Ingelheim’s FENS Award 2012 for Exceptional Research in Neuroscience
This year’s Boehringer Ingelheim FENS Award was granted to Ilka Diester from Stanford University Department of Bioengineering, Stanford, USA...

The Abbott Fund announces $1 million partnership with the Secretary’s International Fund for Women and Girls
The Abbott Fund, has announced a partnership with the U.S. Secretary of State’s International Fund for Women and Girls to empower women and address critical community needs in Burma...

Merck highlights data presentations at the Alzheimer’s Association International Conference 2012
Merck has announced presentations at the upcoming Alzheimer’s Association International Conference (AAIC)...

Abbott focuses on the importance of information management and automation at the AACC Lab Expo
Abbott will feature new solutions to improve data management and automation at this year’s American Association for Clinical Chemistry (AACC) annual meeting...

GSK and Theravance announce regulatory submissions for FF/VI in the US and Europe
GSK and Theravance, Inc., announced the submission of regulatory applications in the US and European Union for the once-daily investigational medicine fluticasone furoate “FF”/vilanterol “VI” (FF/VI)...

Daiichi Sankyo to build production facilities for biopharmaceuticals
Daiichi Sankyo Company, Limited has been approved for the Japanese Ministry of Economy, Trade and Industry’s production facility building grant, which is part of the Ministry’s second production facility building initiative...

Merck Millipore interviewed at ACHEMA 2012
Daniel Stamm, Head of Global Sales Biopharm Process Solutions, Merck Millipore speaks to Freddy White at ACHEMA 2012.

EMD Millipore interviewed at ACHEMA 2012
Christophe Couturier, Vice President – Services and Solutions, EMD Millipore speaks to Freddy White at ACHEMA 2012.

GEA Pharma Systems interviewed at ACHEMA 2012
Frans K.A. Maas, Vice President Sales & Marketing, GEA Pharma Systems speaks to Freddy White, Director of the European Pharmaceutical Review at ACHEMA 2012.